Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models.

New pharmaceutical formulations must be proven as safe and effective before entering clinical trials. Also in the context of pulmonary drug delivery, preclinical models allow testing of novel antimicrobials, reducing risks and costs during their development. Such models allow reducing the complexity of the human lung, but still need to reflect relevant (patho-) physiological features. This review focuses on preclinical pulmonary models, mainly in vitro models, to assess drug safety and efficacy of antimicrobials. Furthermore, approaches to investigate common infectious diseases of the respiratory tract, are emphasized. Pneumonia, tuberculosis and infections occurring due to cystic fibrosis are in focus of this review. We conclude that especially in vitro models offer the chance of an efficient and detailed analysis of new antimicrobials, but also draw attention to the advantages and limitations of such currently available models and critically discuss the necessary steps for their future development.

[1]  Driton Vllasaliu,et al.  Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. , 2010, International journal of pharmaceutics.

[2]  U. Gupta,et al.  Animal Models of Tuberculosis , 2005, Tuberculosis.

[3]  Giuseppe Rodi,et al.  Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report , 2007, Orphanet journal of rare diseases.

[4]  Ping Li,et al.  Autophagy mediates avian influenza H5N1 pseudotyped particle-induced lung inflammation through NF-κB and p38 MAPK signaling pathways. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[5]  P. Byron,et al.  Tobramycin Disposition in the Rat Lung Following Airway Administration , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[6]  F. Ahsan,et al.  Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. , 2004, Journal of pharmaceutical sciences.

[7]  Claus-Michael Lehr,et al.  The cell line NCl-H441 is a useful in vitro model for transport studies of human distal lung epithelial barrier. , 2014, Molecular pharmaceutics.

[8]  A. Hickey,et al.  The guinea pig as a model of infectious diseases. , 2008, Comparative medicine.

[9]  D. Hansell,et al.  Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis , 2000, Thorax.

[10]  Christian Mühlfeld,et al.  Particle and Fibre Toxicology Translocation of Particles and Inflammatory Responses after Exposure to Fine Particles and Nanoparticles in an Epithelial Airway Model , 2022 .

[11]  T. Umino,et al.  TGF-β and glutathione promote tissue repair in cigarette smoke induced injury. , 2007 .

[12]  M. Virji,et al.  Involvement of the autophagy pathway in trafficking of Mycobacterium tuberculosis bacilli through cultured human type II epithelial cells , 2012, Cellular microbiology.

[13]  S. Johnston,et al.  Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.

[14]  A. Amirfazli,et al.  Factors affecting magnetic retention of particles in the upper airways: an in vitro and ex vivo study. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[15]  Qiang Zhang,et al.  Transport of proteins and peptides across human cultured alveolar A549 cell monolayer. , 2004, International journal of pharmaceutics.

[16]  M. Niederman,et al.  Community-Acquired Pneumonia: An Unfinished Battle , 2011, Medical Clinics of North America.

[17]  A. Gutleb,et al.  Potential of coculture in vitro models to study inflammatory and sensitizing effects of particles on the lung. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[18]  J. Cassiman,et al.  Established cell lines used in cystic fibrosis research. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[19]  E. Schwiebert,et al.  Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[20]  D. Baines,et al.  Forskolin-induced Cell Shrinkage and Apical Translocation of Functional Enhanced Green Fluorescent Protein-Human αENaC in H441 Lung Epithelial Cell Monolayers* , 2006, Journal of Biological Chemistry.

[21]  Jeffrey R. Galvin,et al.  From the archives of the AFIP: pulmonary alveolar proteinosis. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.

[22]  A. Goolaerts,et al.  Differentiation of Epithelial Na+ Channel Function , 2005, Journal of Biological Chemistry.

[23]  C. Harris,et al.  Sv40‐induced immortalization and ras‐transformation of human bronchial epithelial cells , 1995, International journal of cancer.

[24]  Karen A Robinson,et al.  Pulmonary Perspective Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations , 2009 .

[25]  W. Koch,et al.  Functional Testing of an Inhalable Nanoparticle Based Influenza Vaccine Using a Human Precision Cut Lung Slice Technique , 2013, PloS one.

[26]  T S Nawrot,et al.  Co-cultures of multiple cell types mimic pulmonary cell communication in response to urban PM10 , 2008, European Respiratory Journal.

[27]  J. Wine The Development of Lung Disease in Cystic Fibrosis Pigs , 2010, Science Translational Medicine.

[28]  B. Ruggeri,et al.  Animal models of human disease: challenges in enabling translation. , 2014, Biochemical pharmacology.

[29]  K. Audus,et al.  Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. , 1998, Experimental cell research.

[30]  Carsten Kneuer,et al.  Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o–: implications for the use of this cell line as an in vitro model for bronchial drug absorption studies , 2002, Cell and Tissue Research.

[31]  Robert L. Hunter,et al.  A Humanized Mouse Model of Tuberculosis , 2013, PloS one.

[32]  S. Shoyele,et al.  Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. , 2006, International journal of pharmaceutics.

[33]  O. Bajolet,et al.  Airway mucus in cystic fibrosis. , 2002, Paediatric respiratory reviews.

[34]  Ben Forbes,et al.  Culture of Calu-3 Cells at the Air Interface Provides a Representative Model of the Airway Epithelial Barrier , 2006, Pharmaceutical Research.

[35]  Yuanyuan Xiao,et al.  Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. , 2007, The Journal of clinical investigation.

[36]  B. Stanton,et al.  Co-culture models of Pseudomonas aeruginosa biofilms grown on live human airway cells. , 2010, Journal of visualized experiments : JoVE.

[37]  M. Camatini,et al.  The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells. , 2013, Toxicology letters.

[38]  A. Hickey,et al.  Inhaled Drug Delivery for Tuberculosis Therapy , 2009, Pharmaceutical Research.

[39]  M. Gumbleton,et al.  The particle has landed--characterizing the fate of inhaled pharmaceuticals. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[40]  C. Turkington,et al.  The Encyclopedia of Infectious Diseases , 1998 .

[41]  M. Bebawy,et al.  Ciprofloxacin Is Actively Transported across Bronchial Lung Epithelial Cells Using a Calu-3 Air Interface Cell Model , 2013, Antimicrobial Agents and Chemotherapy.

[42]  S. Bozinovski,et al.  Recent advances in pre-clinical mouse models of COPD , 2013, Clinical science.

[43]  P. Lackie,et al.  Interactions between endothelial cells and epithelial cells in a combined cell model of airway mucosa: effects on tight junction permeability , 2010, Experimental lung research.

[44]  Ben Forbes,et al.  Human respiratory epithelial cell culture for drug delivery applications. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[45]  Y. Korchev,et al.  Immortalization of human alveolar epithelial cells to investigate nanoparticle uptake. , 2008, American journal of respiratory cell and molecular biology.

[46]  S. Diggle,et al.  Development of an Ex Vivo Porcine Lung Model for Studying Growth, Virulence, and Signaling of Pseudomonas aeruginosa , 2014, Infection and Immunity.

[47]  H. Yonezawa,et al.  Role of IL-17A and IL-10 in the antigen induced inflammation model by Mycoplasma pneumoniae , 2014, BMC Microbiology.

[48]  B. Grant,et al.  Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[49]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[50]  Martin Mohr,et al.  Oxidative stress and inflammation response after nanoparticle exposure: differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways , 2010, Journal of The Royal Society Interface.

[51]  Wei Gao,et al.  Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-β1 in a coculture system , 2010, Clinical and Experimental Medicine.

[52]  Kevin Kendall,et al.  Surfactant protein D (SP-D) alters cellular uptake of particles and nanoparticles , 2013, Nanotoxicology.

[53]  Kathleen J. Menard Whole lung lavage in the treatment of pulmonary alveolar proteinosis. , 2005, Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses.

[54]  K. Juni,et al.  Permeability of Peptides and Proteins in Human Cultured Alveolar A549 Cell Monolayer , 1995, Pharmaceutical Research.

[55]  S. H. Rosen,et al.  Pulmonary alveolar proteinosis. , 1958, The New England journal of medicine.

[56]  R. Ryan,et al.  Modelling Co-Infection of the Cystic Fibrosis Lung by Pseudomonas aeruginosa and Burkholderia cenocepacia Reveals Influences on Biofilm Formation and Host Response , 2012, PloS one.

[57]  G. O’Toole,et al.  In Vitro Analysis of Tobramycin-Treated Pseudomonas aeruginosa Biofilms on Cystic Fibrosis-Derived Airway Epithelial Cells , 2008, Infection and Immunity.

[58]  I. Kilty,et al.  The role of IFN-γ in regulation of IFN-γ-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures , 2007, Respiratory research.

[59]  U. Römling,et al.  Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. , 2005, Journal of medical microbiology.

[60]  Robert Landsiedel,et al.  In vivo-in vitro comparison of acute respiratory tract toxicity using human 3D airway epithelial models and human A549 and murine 3T3 monolayer cell systems. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[61]  A. Harnden,et al.  British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011 , 2011, Thorax.

[62]  M. Gumbleton,et al.  P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers , 2007, Cell and Tissue Research.

[63]  B. Penke,et al.  In Vitro and in Vivo Nuclear Factor-κB Inhibitory Effects of the Cell-Penetrating Penetratin Peptide , 2006, Molecular Pharmacology.

[64]  Daniel J Klionsky,et al.  Development by self-digestion: molecular mechanisms and biological functions of autophagy. , 2004, Developmental cell.

[65]  A. Winkelmann,et al.  The Clara cell: a “Third Reich eponym”? , 2010, European Respiratory Journal.

[66]  W. Kummer,et al.  Barrier functions and paracellular integrity in human cell culture models of the proximal respiratory unit. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[67]  W. Craig,et al.  Animal model pharmacokinetics and pharmacodynamics: a critical review. , 2002, International journal of antimicrobial agents.

[68]  C. Lehr,et al.  Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. , 2013, The Lancet. Respiratory medicine.

[69]  J. Schwartzman,et al.  In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. , 2012, The Journal of antimicrobial chemotherapy.

[70]  C. Ehrhardt,et al.  Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. , 2013, Therapeutic delivery.

[71]  B. Rothen‐Rutishauser,et al.  Macrophages and dendritic cells express tight junction proteins and exchange particles in an in vitro model of the human airway wall. , 2011, Immunobiology.

[72]  Armin Braun,et al.  Assessment of immunotoxicity using precision-cut tissue slices , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[73]  S. Chan,et al.  Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension. , 2013, International journal of pharmaceutics.

[74]  H. McShane,et al.  A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data☆ , 2014, Tuberculosis.

[75]  E. Swiatlo,et al.  Deletion of arcD in Streptococcus pneumoniae D39 Impairs Its Capsule and Attenuates Virulence , 2013, Infection and Immunity.

[76]  S. Mcphee,et al.  Pathophysiology of Disease: An Introduction to Clinical Medicine , 1995 .

[77]  Daniel C Leslie,et al.  A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.

[78]  Karen A Robinson,et al.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.

[79]  N. Høiby Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis , 2011, BMC medicine.

[80]  Mattias Svensson,et al.  Modeling Mycobacterium tuberculosis early granuloma formation in experimental human lung tissue , 2013, Disease Models & Mechanisms.

[81]  C. Ehrhardt,et al.  Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o- , 2006, Cell and Tissue Research.

[82]  Bruce A. Stanton,et al.  Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. , 2008, Pulmonary pharmacology & therapeutics.

[83]  Kirsten Peters,et al.  Lung epithelial cell lines in coculture with human pulmonary microvascular endothelial cells: development of an alveolo-capillary barrier in vitro , 2004, Laboratory Investigation.

[84]  Christine Pohl,et al.  Inflammatory and cytotoxic responses of an alveolar-capillary coculture model to silica nanoparticles: Comparison with conventional monocultures , 2011, Particle and Fibre Toxicology.

[85]  E. Marchiori,et al.  Comparative study of clinical, pathological and HRCT findings of primary alveolar proteinosis and silicoproteinosis. , 2012, European journal of radiology.

[86]  L. Ramakrishnan Revisiting the role of the granuloma in tuberculosis , 2012, Nature Reviews Immunology.

[87]  Claus-Michael Lehr,et al.  Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery. , 2014, Advanced drug delivery reviews.

[88]  Jennifer M. Smith,et al.  Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. , 2005, Biomaterials.

[89]  S. Richter,et al.  Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial Eradication at Birth , 2010, Science Translational Medicine.

[90]  J. Elborn,et al.  Treatment of lung infection in patients with cystic fibrosis: current and future strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[91]  Bin Chen,et al.  Immunization against Multidrug-Resistant Acinetobacter baumannii Effectively Protects Mice in both Pneumonia and Sepsis Models , 2014, PloS one.

[92]  A. Cuervo Autophagy: in sickness and in health. , 2004, Trends in cell biology.

[93]  Rachael M. Crist,et al.  Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity , 2012, Particle and Fibre Toxicology.

[94]  K. Roemer,et al.  Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C , 2002, Cell and Tissue Research.

[95]  D. Ingber,et al.  Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.

[96]  B. Meibohm,et al.  In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. , 2010, Future medicinal chemistry.

[97]  M. Pallardy,et al.  Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. , 2013, International journal of pharmaceutics.

[98]  R. Pandey,et al.  Antitubercular inhaled therapy: opportunities, progress and challenges. , 2005, Journal of Antimicrobial Chemotherapy.

[99]  Claus-Michael Lehr,et al.  An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[100]  J. Juarez,et al.  CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria , 2013, Proceedings of the National Academy of Sciences.

[101]  P. Dubruel,et al.  An impaired alveolar-capillary barrier in vitro: effect of proinflammatory cytokines and consequences on nanocarrier interaction , 2010, Journal of The Royal Society Interface.

[102]  S. Ranganathan,et al.  Pneumonia and Other Respiratory Infections , 2009, Pediatric Clinics of North America.

[103]  R. Pandey,et al.  Nanomedicine and experimental tuberculosis: facts, flaws, and future. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[104]  R. Barrios Animal Models of Lung Disease , 2009 .

[105]  B. Maycher,et al.  Radiological imaging in pneumonia: recent innovations , 2007, Current opinion in pulmonary medicine.

[106]  S. Molin,et al.  Novel Mouse Model of Chronic Pseudomonas aeruginosa Lung Infection Mimicking Cystic Fibrosis , 2005, Infection and Immunity.

[107]  C. Alexander,et al.  Epithelial toxicity of alkylglycoside surfactants. , 2013, Journal of pharmaceutical sciences.

[108]  Corona M. Cassidy,et al.  Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: a pilot study. , 2011, Photodiagnosis and photodynamic therapy.

[109]  N. A. Whitehead,et al.  Quorum sensing as a population-density-dependent determinant of bacterial physiology. , 2001, Advances in microbial physiology.

[110]  C. Deb,et al.  Human Granuloma In Vitro Model, for TB Dormancy and Resuscitation , 2013, PloS one.

[111]  C. Di Serio,et al.  Adaptation of Pseudomonas aeruginosa in Cystic Fibrosis Airways Influences Virulence of Staphylococcus aureus In Vitro and Murine Models of Co-Infection , 2014, PloS one.

[112]  R. Devlin,et al.  TLR-2 is involved in airway epithelial cell response to air pollution particles. , 2005, Toxicology and applied pharmacology.

[113]  C. Bai,et al.  Therapeutic role of terbutaline in a rat whole-lung lavage model , 2011, Experimental lung research.

[114]  Z. Borok,et al.  A Useful In Vitro Model for Transport Studies of Alveolar Epithelial Barrier , 2001, Pharmaceutical Research.

[115]  José Vassallo,et al.  Overexpression of ANXA1 in Penile Carcinomas Positive for High-Risk HPVs , 2013, PloS one.

[116]  S. Anderson,et al.  The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia. , 2013, Molecular pharmaceutics.

[117]  D. Klee,et al.  Influence of particle size and material properties on mucociliary clearance from the airways. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[118]  M. Bates,et al.  Human monocytic cells direct the robust release of CXCL10 by bronchial epithelial cells during rhinovirus infection , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[119]  Jiyong Jing,et al.  Pulmonary alveolar proteinosis in China: A systematic review of 241 cases , 2009, Respirology.

[120]  Gerhard Scheuch,et al.  Clinical perspectives on pulmonary systemic and macromolecular delivery. , 2006, Advanced drug delivery reviews.

[121]  Jeffrey C. Pommerville,et al.  Alcamo's Fundamentals of Microbiology , 2004 .

[122]  A. Perkins,et al.  Evaluation of the clearance characteristics of bioadhesive systems in humans. , 1999, International journal of pharmaceutics.

[123]  Emily V. Chambers,et al.  Mycoplasma pneumoniae host-pathogen studies in an air-liquid culture of differentiated human airway epithelial cells. , 2007, Microbial pathogenesis.

[124]  C. Kirkpatrick,et al.  Side-specific effects by cadmium exposure: apical and basolateral treatment in a coculture model of the blood-air barrier. , 2010, Toxicology and applied pharmacology.

[125]  V. Haley,et al.  Quantifying Sources of Bias in National Healthcare Safety Network Laboratory-Identified Clostridium difficile Infection Rates , 2014, Infection Control & Hospital Epidemiology.

[126]  N. Ozaki,et al.  Up-regulation of surfactant protein production in a mouse model of secondary pulmonary alveolar proteinosis. , 2009, American journal of respiratory cell and molecular biology.

[127]  L. Saiman,et al.  Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update , 2014, Infection Control & Hospital Epidemiology.

[128]  A. Dunn,et al.  Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[129]  M. Karimi,et al.  Features of idiopathic pulmonary alveolar proteinosis in high resolution computed tomography , 2014, Polish journal of radiology.

[130]  Nilesh Patel,et al.  Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[131]  B. Forbes,et al.  Inflammatory Response and Barrier Properties of a New Alveolar Type 1-Like Cell Line (TT1) , 2009, Pharmaceutical Research.

[132]  M. Schluchter,et al.  Murine models of chronic Pseudomonas aeruginosa lung infection , 2002, Laboratory animals.

[133]  C. Lehr,et al.  Isolation, cultivation, and application of human alveolar epithelial cells. , 2012, Methods in molecular biology.

[134]  Min-Ki Lee,et al.  Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. , 2007, Journal of pharmaceutical sciences.

[135]  M. Maciá,et al.  Antimicrobial susceptibility testing in biofilm-growing bacteria. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[136]  Forbes,et al.  Human airway epithelial cell lines for in vitro drug transport and metabolism studies. , 2000, Pharmaceutical science & technology today.

[137]  C. Lehr,et al.  Cell culture models of the respiratory tract relevant to pulmonary drug delivery. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[138]  C. Lehr,et al.  Embryonic Chicken Trachea as a New In Vitro Model for the Investigation of Mucociliary Particle Clearance in the Airways , 2008, AAPS PharmSciTech.

[139]  R. Vanbever,et al.  Preclinical models for pulmonary drug delivery , 2009, Expert opinion on drug delivery.

[140]  R. Hartmann,et al.  Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[141]  S. Mitragotri,et al.  Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge--an ex vivo and in silico approach. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[142]  Roger L. White What In Vitro Models of Infection Can and Cannot Do , 2001, Pharmacotherapy.

[143]  S. Kirchner,et al.  Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung , 2012, Journal of visualized experiments : JoVE.

[144]  M. Cosio,et al.  Inflammation of the airways and lung parenchyma in COPD: role of T cells. , 2002, Chest.

[145]  T. Murphy,et al.  Pseudomonas aeruginosa in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[146]  Gerald B. Pier,et al.  Lung Infections Associated with Cystic Fibrosis , 2002, Clinical Microbiology Reviews.

[147]  J. Crapo,et al.  Allometric relationships of cell numbers and size in the mammalian lung. , 1992, American journal of respiratory cell and molecular biology.

[148]  M. Fliegauf,et al.  Mucociliary Clearance Defects in a Murine In Vitro Model of Pneumococcal Airway Infection , 2013, PloS one.

[149]  Valérie Zuang,et al.  A Modular Approach to the ECVAM Principles on Test Validity , 2004, Alternatives to laboratory animals : ATLA.

[150]  A. Meijer,et al.  Nanoparticles as drug delivery system against tuberculosis in zebrafish embryos: direct visualization and treatment. , 2014, ACS nano.

[151]  D. Newman,et al.  Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. , 2012, American journal of respiratory cell and molecular biology.

[152]  J. Colmer-Hamood,et al.  Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium , 2012, BMC Microbiology.

[153]  J. Bueno Antitubercular In Vitro Drug Discovery: Tools for Begin the Search , 2012 .

[154]  H. Junginger,et al.  Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[155]  Song Huang,et al.  In vitro organ culture models of asthma , 2009 .

[156]  M. Cavet,et al.  Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells , 1997, Antimicrobial agents and chemotherapy.

[157]  P. Paré,et al.  Amplification of inflammation in emphysema and its association with latent adenoviral infection. , 2001, American journal of respiratory and critical care medicine.

[158]  Christopher S. Stach,et al.  Vaccination against Staphylococcus aureus pneumonia. , 2014, The Journal of infectious diseases.

[159]  Arno C Gutleb,et al.  An improved 3D tetraculture system mimicking the cellular organisation at the alveolar barrier to study the potential toxic effects of particles on the lung , 2013, Particle and Fibre Toxicology.

[160]  M. Sakagami,et al.  In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. , 2006, Advanced drug delivery reviews.

[161]  D. Steinemann,et al.  Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. , 2013, American journal of respiratory and critical care medicine.

[162]  R. Hartmann,et al.  Identification of small-molecule antagonists of the Pseudomonas aeruginosa transcriptional regulator PqsR: biophysically guided hit discovery and optimization. , 2012, ACS chemical biology.

[163]  Jeremy L. Steinbacher,et al.  Differences in gene expression and cytokine production by crystalline vs. amorphous silica in human lung epithelial cells , 2012, Particle and Fibre Toxicology.

[164]  B. Rubin Mucus structure and properties in cystic fibrosis. , 2007, Paediatric respiratory reviews.

[165]  F. Tuya,et al.  A Meta-Analysis of Seaweed Impacts on Seagrasses: Generalities and Knowledge Gaps , 2012, PloS one.

[166]  Peter Gehr,et al.  A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. , 2005, American journal of respiratory cell and molecular biology.

[167]  Ali Khademhosseini,et al.  In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[168]  V. H. Lee,et al.  Monolayers of Human Alveolar Epithelial Cells in Primary Culture for Pulmonary Absorption and Transport Studies , 1999, Pharmaceutical Research.

[169]  C. Ehrhardt,et al.  In vitro cell culture models for the assessment of pulmonary drug disposition , 2008 .

[170]  M. Gaca,et al.  In Vitro Models of Chronic Obstructive Pulmonary Disease (COPD) , 2011 .

[171]  B. Oliver,et al.  TGFβ1 induces IL‐6 and inhibits IL‐8 release in human bronchial epithelial cells: The role of Smad2/3 , 2010, Journal of cellular physiology.

[172]  Robert Landsiedel,et al.  Applicability of rat precision-cut lung slices in evaluating nanomaterial cytotoxicity, apoptosis, oxidative stress, and inflammation. , 2014, Toxicology and applied pharmacology.

[173]  A. Dannenberg Perspectives on Clinical and Preclinical Testing of New Tuberculosis Vaccines , 2010, Clinical Microbiology Reviews.

[174]  T. Srichana,et al.  Inhaled pyrazinamide proliposome for targeting alveolar macrophages , 2012, Drug delivery.

[175]  E. Weibel,et al.  Functional design of the human lung for gas exchange , 2008 .